叶酸-白蛋白包覆阳离子纳米脂质载体的制备及体内外评价
Preparation and in vitro and in vivo evaluation of folate-BSA-coated cationic nanostructure lipid carriers
-
摘要: 合成叶酸-白蛋白靶向材料，通过薄膜分散法制备白蛋白包覆阳离子脂质纳米载体(BSA-cNLCs)和叶酸-白蛋白包覆阳离子脂质纳米载体(FA-BSA-cNLCs)。对两者粒径、外观、包封率、载药量、体外细胞摄取、血液和肿瘤药代动力学和药效学进行考察。结果表明，BSA-cNLCs和FA-BSA-cNLCs粒径分别为81.4和79.8 nm，Zeta电位分别为+5.12和+3.74 mV，透射电镜照片表明两者均为圆整的类球形结构。两者紫杉醇包封率都大于97%，载药量在3.7%左右。体外细胞试验证实，高表达叶酸受体的SKOV3对FA-BSA-cNLCs的摄取显著高于BSA-cNLCs，说明FA-BSA-cNLCs对SKOV3具有明显的靶向性。血液及肿瘤药代动力学显示两者体内药代动力学行为无明显差异，证实表面修饰叶酸不影响制剂的体内行为。药效学试验显示，BSA-cNLCs和FA-BSA-cNLCs抑瘤率分别为72.08%和80.75%。可见FA-BSA-cNLCs在一定程度上提高了体内外抗肿瘤疗效，在肿瘤的治疗中具有较好应用前景。Abstract: Folic acid(FA)was conjugated with bovine serum albumin(BSA)to form targeting material. BSA-coated cationic nanostructure lipid carriers(BSA-cNLCs)and folate-BSA-coated cationic nanostructure lipid carriers(FA-BSA-cNLCs)were prepared by film dispersion. The particle sizes of BSA-cNLCs and FA-BSA-cNLCs were 81. 4 nm and 79. 8 nm, while their Zeta potentials were +5. 12 mV and +3. 74 mV. Both nanostructure lipid carriers showed spherical shape. Paclitaxel encapsulation efficiency of them were more than 97%, with drug loading efficiency of about 3. 7%. In vitro experiments confirmed that the uptake of FA-BSA-cNLCs by overexpressed folate receptor SKOV3 cells was significantly higher than that of BSA-cNLCs, demonstrating that FA-BSA-cNLCs were obviously targeted to SKOV3. Blood and tumor pharmacokinetics showed that there was no significant differences between BSA-cNLCs and FA-BSA-cNLCs. This suggested that modified FA on the surface of the preparation had no effect on its in vivo behavior. Tumor inhibition of BSA-cNLCs and FA-BSA-cNLCs were 72. 08% and 80. 75%, repectively, which indicateds that FA-BSA-cNLCs improve anticancer efficacy in vitro and in vivo, and that it could be a potential preparation for the treatment of cancer.
-
-
[1] Zhang LH,He YN,Ma GL,et al.Preparation,characterization,in vitro and in vivo studies on folate-targeted biodegradable polymersomes loaded with paclitaxel[J].Chin Pharm J(中国药学杂志),2010, 45(22):1742-1748. [2] Zhao DM,Zhao XH,Zu YG,et al.Preparation,characterization,and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles[J].Int J Nanomedicine,2010, 5:669-677. [3] Sudimack J,Lee RJ.Targeted drug delivery via the folate receptor[J].Adv Drug Deliv Rev,2000, 41(2):147-162. [4] Zhang L,Hou S,Mao J,et al.Study on the tumor cell targetability of folate-conjugated albumin nanoparticles[J].J Sichuan Univ(Med Sci Edi)(四川大学学报:医学版),2004, 35(4):165-168. [5] Li S,Xiao YY,Su ZG,et al.Preparation of BSA-coated cationic nanostructure lipid carriers and phamacokinetics and biodistribution after intravenous injection[J].J China Pharm Univ (中国药科大学学报),2012, 43(5):406-411. [6] Du C,Deng DW,Shan L,et al.A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery[J].Biomaterials,2013, 34(12):3087-3097. [7] Huo MR,Zhou JP,Wei Y,et al.Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice[J].Acta Pharm Sin(药学学报),2006, 41(9):867-872. [8] Li XF,Ma YJ,Zhang X,et al.Preparation of fluorescent probe coumarin-6 loaded PLGA nanoparticles[J].Chin J Mod Appl Pharm(中国现代应用药学),2011, 28(8):740-744. [9] Zhang L,Huo S,Lu Y,et al.Study on biodistribution and pharmacodynamics of folate receptor-mediated mitoxantrone-loaded albumin nanoparticles[J].Chin Pharm J(中国药学杂志),2007, 42(9):676-678. -
期刊类型引用(2)
1. 王永健，郭明. 新型BCR-ABL抑制剂的设计合成与构效关系. 中国药科大学学报. 2024(03): 357-366 . 
本站查看
2. 关淑文，高博韬，肖将尉. 基于细胞薄膜技术构建可长期维持细胞色素P450活性的体外人类三维肝脏模型. 生物医学工程学杂志. 2022(04): 776-783 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 1644
- HTML全文浏览量: 0
- PDF下载量: 2536
- 被引次数: 2
下载:
